Table 7.
Multivariable Logistic Regression Analysis of Number of Abnormal Biomarker Levels and the Odds of Developing CRS1
| No. of Abnormal Biomarkersa | No‐CRS1 (n, %) | CRS1 (n, %) | Adjusted OR (95% CI)b | P Value |
|---|---|---|---|---|
| 0 | 657 (99.4) | 4 (0.6) | 1 | ··· |
| 1 | 620 (96.3) | 24 (3.7) | 8.907 (2.065‐38.409) | 0.003 |
| ≥2 | 426 (77.5) | 124 (22.5) | 36.188 (8.534‐153.455) | <0.001 |
ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; CI, confidence interval; CRS1, cardiorenal syndrome type 1; eGFR, estimated glomerular filtration rate; hs‐CRP, high‐sensitivity C‐reactive protein; NT‐proBNP, amino‐terminal pro–brain natriuretic peptide; OR, odds ratio.
Cutoff values for abnormal biomarker levels were eGFR≤71.29 mL/(min·1.73 m2), NT‐proBNP≥2573 pg/mL, and hs‐CRP≥8.03 mg/L.
Adjusted by age, sex, hemoglobin at admission, hematocrit at admission, albumin at admission, glucose at admission, previous coronary artery disease, previous hypertension, previous diabetes mellitus, previous chronic kidney disease, angiography, ACEI and/or ARB use after admission, and diuretic use after admission.